Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,127.7
5.2 (0.17%)

 

  • STI Straits Times Index
    3,127.7
    5.2 (0.17%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,602.5
    7.9 (0.49%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,048.7
    -221.3 (-0.84%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,883.4
    3.1 (0.11%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,628.0
    9.4 (0.05%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,239.2
    -13.7 (-0.22%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,951.0
    -13.6 (-0.69%)
    Index delayed 20 minutes
  • XAO XAO
    6,593.0
    20.4 (0.31%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 792.8M
  • Value: 897.2M
  • Rise: 154
  • Fall: 151
  • Unch: 530

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
LionGold0.001-
ThaiBev0.930+0.005
YZJ Shipbldg SGD0.930-0.035
SingTel3.240+0.050
Rex Intl0.076-0.001
MMP Resources^0.003-0.001
Kep Infra Tr0.515+0.005
Koh Eco0.052+0.001
RHT HealthTrust0.019+0.001
Frasers L&I Tr1.190-0.030

World Indices

World Indices
Name Last Change
Nasdaq 8,020.2 +71.7
HSI 26,048.7 -221.3
HSCEI 10,122.9 -54.4
Jakarta 6,239.2 -13.7
Nikkei 225 20,628.0 +9.4
SSE Comp 2,883.4 +3.1
Shanghai A 3,020.7 +3.3
Shanghai B 264.3 -0.5
PSE Comp 0.0
KOSPI 1,951.0 -13.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NEUBASE THERAPEUTICS INC NEUBASE THERAPEUTICS
Updated on 21 Aug 2019 (End of trading day)
Last (USD): 4.670 Change: -0.130 High: 4.940 Remarks: -
Change (%): -2.71 Low: 4.600
Open 4.940 Yesterday's Close 4.8
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 42,469 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.77545 Trailing EPS (USD) e -0.52381 NAV (USD) b 0.5277
PE a - Trailing PE f - Price / NAV b 8.8497
Dividend (USD) d - Cash In Hand (USD) g 0.1247 Issued & Paid-up Shares c 17,070,000
Dividend Yield (%) d - Price / Cash In Hand g 37.450 Treasury Shares h -
Beta - 75 Daysi 0.424 R-Squared - 75 Days(%)i 0.76 Market Cap (M) 79.717
Beta - 500 Daysi 0.417 R-Squared - 500 Days (%)i 0.78 Enterprise Value (M) 77.588
Piotroski F Score 2 Exchange Code NBSE Par Value ( $ ) n.a.
52 Weeks Volatility (%) n.a. Free Float (%) 60.9
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 16 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 15 Jul 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NEUBASE THERAPEUTICS INC NASDAQ 79.717 - - 8.8497 -
Industry Pharmaceuticals: Major NASDAQ 1,493.286 211.615 411.642 2.0294 0.011
Local Peer SANOFI SPON ADS ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 108,162.864 21.228 26.297 1.6854 2.661
Local Peer GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 NASDAQ 5,806.249 8.249 9.018 1.1604 3.504
Local Peer ALLAKOS INC NASDAQ 4,343.982 - - 28.5510 -
Local Peer HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS NASDAQ 2,719.626 - - 7.8173 -
Local Peer REATA PHARMACEUTICALS INC NASDAQ 2,262.128 - - -67.5783 -
Local Peer AKCEA THERAPEUTICS INC NASDAQ 2,052.286 - - 5.5672 -
Local Peer APELLIS PHARMACEUTICALS INC NASDAQ 1,908.332 - - 11.9955 -
Local Peer TRICIDA INC NASDAQ 1,738.528 - - 5.0124 -
Local Peer TURNING POINT THERAPEUTICS INC NASDAQ 1,638.246 - - 6.6081 -
Local Peer G1 THERAPEUTICS IN NASDAQ 1,420.621 - - 4.5435 -
Local Peer RA PHARMACEUTICALS INC NASDAQ 1,405.278 - - 8.0908 -
Local Peer ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS NASDAQ 1,335.727 - - 3.5988 -
Other Local Peers PHIBRO ANIMAL HEALTH CORP (NASDAQ), GOSSAMER BIO INC (NASDAQ), ATHENEX INC (NASDAQ), ODONATE THERAPEUTICS LLC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), PETIQ INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), DOVA PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), EVOLUS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), OBSEVA SA (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), AC IMMUNE SA (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), AKORN INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), FORTY SEVEN INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), MUSTANG BIO INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), EMMAUS LIFE SCIENCES INC NEW (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), IMMUNIC INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), LIQUIDIA TECHNOLOGIES INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), ASSERTIO THERAPEUTICS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), NOVAN INC (NASDAQ), EYENOVIA INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TELIGENT INC NEW (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ENTERA BIO LTD (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), EDESA BIOTECH INC (NASDAQ), ESSA PHARMA INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), SIENNA BIOPHARMACEUTICALS INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), GENPREX INC (NASDAQ), NOVUS THERAPEUTICS INC (NASDAQ), GEMPHIRE THERAPEUTICS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ)
Global Peer JOHNSON & JOHNSON NYSE 347,130.030 22.693 21.255 5.7108 2.715
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 227,767.486 18.020 19.950 4.4290 1.869
Global Peer MERCK & CO INC NYSE 222,522.626 35.775 23.769 8.0522 2.319
Global Peer PFIZER INC NYSE 192,867.714 17.294 15.248 3.2387 4.091
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 119,170.725 55.394 54.522 8.7962 2.913
Global Peer ELI LILLY AND COMPANY NYSE 107,607.162 33.294 25.849 38.7000 2.210
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 101,489.405 21.008 17.709 22.0650 5.001
Global Peer ABBVIE INC NYSE 99,856.539 17.652 24.415 -11.6573 5.850
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 96,517.859 15.786 16.809 - 2.194
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 78,140.733 15.882 12.533 4.8689 3.346
Other Global Peers TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), WUXI APPTEC (HKEx), HANSOH PHARMA (HKEx), CHINARES PHARMA (HKEx), INNOVENT BIO-B (HKEx), JUNSHI BIO-B (HKEx), CMS (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CHINAGRANDPHARM (HKEx), CSTONE PHARMA-B (HKEx), ZYMEWORKS INC (NYSE), CANSINOBIO-B (HKEx), UNITED LAB (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), HUA MEDICINE-B (HKEx), FUSEN PHARM (HKEx), IGBB (Bursa), DAWNRAYS PHARMA (HKEx), LANNETT CO INC (NYSE), AFT PHARMACEUTICALS LTD (ASX), NC HEALTHCARE (HKEx), AGEX THERAPEUTICS INC (NYSE American), Merck Tbk. (IDX), Phapros Tbk. (IDX), CHARMACY PHAR (HKEx), MEDLAB CLINICAL LIMITED (ASX), PALLA PHARMA LTD (ASX), KOTRA (Bursa), NEP INTERLONG (HKEx), Hyphens Pharma (SGX), CRESO PHARMA LTD (ASX), BIOHLDG (Bursa), MMJ GROUP HOLDINGS LTD (ASX), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), NOXOPHARM LTD (ASX), NOVA (Bursa), SINOLIFE UTD (HKEx), EXOPHARM LTD (ASX), RECCE PHARMACEUTICALS LTD (ASX), Star Pharm^ (SGX), FARMAFORCE LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), Merck Sharp Dohme Pharma Tbk. (IDX), RACE ONCOLOGY LTD (ASX), FIJI KAVA LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.275
-5.56 %
10 Days --0.490
-9.50 %
20 Days -+0.620
+15.31 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 3.360 - 6.230 Change From 1 Year Low +1.310 % Change From 1 Year Low (%) +38.99
Change From 1 Year High -1.560 % Change From 1 Year High (%) -25.04
2 Years Range 3.360 - 6.230 Change From 2 Years Low +1.310 % Change From 2 Years Low (%) +38.99
Change From 2 Years High -1.560 % Change From 2 Years High (%) -25.04
5 Years Range 3.360 - 6.230 Change From 5 Years Low +1.310 % Change From 5 Years Low (%) +38.99
Change From 5 Years High -1.560 % Change From 5 Years High (%) -25.04
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

NeuBase Therapeutics, Inc. engages in the development of drugs for patients with genetic neurological disorder. Its pipelines include Huntington's Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA.

Historical Price Data

Date Open High Low Close Volume VWAP
21 Aug 2019 4.940 4.940 4.600 4.670 42,469 -
20 Aug 2019 5.100 5.190 4.650 4.800 54,820 -
19 Aug 2019 4.650 5.090 4.650 5.090 48,144 -
16 Aug 2019 4.940 5.075 4.650 4.750 54,287 -
15 Aug 2019 4.980 5.200 4.900 4.945 54,155 -
14 Aug 2019 5.210 5.364 4.820 4.880 63,118 -
13 Aug 2019 5.250 5.470 5.150 5.190 37,763 -
12 Aug 2019 5.190 5.620 5.096 5.410 60,382 -
09 Aug 2019 5.140 5.479 5.140 5.180 58,772 -
08 Aug 2019 5.156 5.340 5.021 5.160 74,211 -
07 Aug 2019 5.110 5.300 4.873 5.040 87,109 -
06 Aug 2019 5.700 5.700 5.150 5.150 123,113 -
05 Aug 2019 5.050 5.650 5.050 5.550 168,212 -
02 Aug 2019 5.010 5.550 5.010 5.300 82,006 -
01 Aug 2019 5.100 5.650 4.905 5.320 368,771 -
31 Jul 2019 4.610 5.270 4.610 5.080 451,468 -
30 Jul 2019 4.180 4.730 4.170 4.480 209,826 -
29 Jul 2019 4.170 4.200 4.020 4.130 103,218 -
26 Jul 2019 4.090 4.170 3.950 3.990 109,657 -
25 Jul 2019 4.170 4.269 3.900 4.050 88,744 -
24 Jul 2019 3.940 4.330 3.769 4.170 143,245 -
23 Jul 2019 3.410 4.169 3.360 4.140 194,592 -
Summary
Current 2 Weeks
(08 Aug 2019 to 21 Aug 2019)
5.156 5.620 4.600 4.670 548,121 -
Previous 2 Weeks
(25 Jul 2019 to 07 Aug 2019)
4.170 5.620 3.900 5.040 1,792,124 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.